To those holding this down, page-19

Yes good point, 600 subjects as part of a study is what the announcement said - not pedantic at all, happy to be corrected. The announcement also talks about it being in parallel to the trial which is slightly at odds to the hope that this may happen post-approval. I am pretty confident, however, that post-approval is what SI was suggesting they would negotiate through Teva when questioned. I do remember the analyst asking the questions was quite determined to ask him about the numbers not being reduced in reality and SI was clear that, whilst nothing was certain, that post-approval for the study was part of the discussion with the FDA. You have to think that if the results are repeated from phase 2 and end-points are met whilst the control group have negative outcomes, it is going to be a harsh decision if approval is not expedited with a post-approval study being required also